Genotypos Private Diagnostic Laboratory Of Molecular And Cytogenetic Analysis
Genotypos Private Diagnostic Laboratory Of Molecular And Cytogenetic Analysis is recorded as a service provider in 10 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 10 of 10 trials · Latest update first
A multicenter, open label, randomized phase II study comparing daratumumab combined with bortezomib-cyclophosphamide-dexamethasone (Dara-VCd) versus the association of bortezomib-thalidomide-dexamethasone (VTd) as pre transplant induction and post transplant consolidation, both followed by a maintenance phase with ixazomib alone or in combination with daratumumab, in newly diagnosed multiple myeloma (MM) young patients eligible for autologous stem cell transplantation
Sponsor European Myeloma Network B.V.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A phase 2 study of Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis
Sponsor European Myeloma Network B.V.
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Study of Isatuximab in combination with Bortezomib, Cyclophosphamide and Dexamethasone followed by isatuximab and lenalidomide maintenance in Newly Diagnosed Patients with Multiple Myeloma and severe Renal Impairment
Sponsor Hellenic Society Of Hematology
- Start (EU)
- Latest update
- Estimated end
- Not reported
An Exploratory, First-in-Human, study to investigate the safety and preliminary efficacy of InvivoLPrint-U-Therapy, a combination of an advanced therapy medicinal product (ATMP) of expanded autologous urothelial cells with an in vivo bioprinter for administration during orthotopic neobladder surgery
Sponsor Phosprint S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 2 Study of Isatuximab in combination with Pomalidomide and Dexamethasone in MM Patients who received one prior line of therapy containing Lenalidomide and a Proteasome Inhibitor
Sponsor Hellenic Society Of Hematology
- Start (EU)
- Latest update
- Estimated end
- Not reported
Daratumumab combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extramedullary Disease
Sponsor European Myeloma Network B.V.
- Start (EU)
- Latest update
- Estimated end
A PHASE 1/2, DOSE AND SCHEDULE EVALUATION STUDY TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN ADMINISTERED IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE WITH OR WITHOUT DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA PREVIOUSLY TREATED WITH ONE TO THREE LINES OF THERAPY WHO ARE LENALIDOMIDE REFRACTORY
Sponsor Hellenic Society Of Hematology
- Start (EU)
- Latest update
- Estimated end
- Not reported
A phase 1/2, dose and schedule evaluation study to investigate the safety and clinical activity of belantamab mafodotin administered in combination with lenalidomide and dexamethasone in patients with transplant ineligible newly diagnosed multiple myeloma
Sponsor Hellenic Society Of Hematology
- Start (EU)
- Latest update
- Estimated end
- Not reported
A PHASE 1/2, DOSE AND SCHEDULE EVALUATION STUDY TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN ADMINISTERED IN COMBINATION WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TRANSPLANT INELIGIBLE
Sponsor Hellenic Society Of Hematology
- Start (EU)
- Latest update
- Estimated end
- Not reported
A PHASE 1/2, DOSE AND SCHEDULE EVALUATION STUDY TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN ADMINISTERED IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TRANSPLANT INELIGIBLE
Sponsor Hellenic Society Of Hematology
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Genotypos Private Diagnostic Laboratory Of Molecular And Cytogenetic Analysis?
The 2026-10-09 snapshot links Genotypos Private Diagnostic Laboratory Of Molecular And Cytogenetic Analysis to 10 distinct CTIS trials. Recorded services include Laboratory services, FISH assessment, Histopathology, (Fluorescence in situ hybridization) FISH, HBV DNA, among 6 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Genotypos Private Diagnostic Laboratory Of Molecular And Cytogenetic Analysis?
Therapeutic-area tags are not recorded in this snapshot. Study-phase tags are not recorded. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Genotypos Private Diagnostic Laboratory Of Molecular And Cytogenetic Analysis conducted?
The linked trials record locations in 6 countries, including Greece, Italy, Czechia, Germany, France. These are trial locations, not confirmed office locations or countries where Genotypos Private Diagnostic Laboratory Of Molecular And Cytogenetic Analysis delivered services.
What can this page tell me about Genotypos Private Diagnostic Laboratory Of Molecular And Cytogenetic Analysis's trial experience?
Browse 10 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under Genotypos Private Diagnostic Laboratory Of Molecular And Cytogenetic Analysis. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Genotypos Private Diagnostic Laboratory Of Molecular And Cytogenetic Analysis S.A
- Genotypos Private Diagnostic Laboratory Of Molecular And Cytogenetic Analysis S.A.